Published in J Clin Invest on December 01, 1995
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol (2011) 2.60
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J Lipid Res (2008) 2.51
Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet. Circ Res (2005) 2.06
Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med (2006) 1.81
Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels. Arterioscler Thromb Vasc Biol (2010) 1.79
The role of dysfunctional HDL in atherosclerosis. J Lipid Res (2008) 1.73
Cholesterol, inflammation and innate immunity. Nat Rev Immunol (2015) 1.72
High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol (2012) 1.70
Transcript-selective translational silencing by gamma interferon is directed by a novel structural element in the ceruloplasmin mRNA 3' untranslated region. Mol Cell Biol (2003) 1.53
Lipoprotein profile in limited systemic sclerosis. Rheumatol Int (2005) 1.52
Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem (2009) 1.51
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest (1997) 1.45
Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein. J Biol Chem (2009) 1.42
HDL remodeling during the acute phase response. Arterioscler Thromb Vasc Biol (2008) 1.40
Combined statin and niacin therapy remodels the high-density lipoprotein proteome. Circulation (2008) 1.38
The HDL proteome: a marker--and perhaps mediator--of coronary artery disease. J Lipid Res (2008) 1.35
Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology (Oxford) (2014) 1.34
An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med (2014) 1.33
Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease. EMBO Mol Med (2012) 1.26
Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis. Rheumatology (Oxford) (2012) 1.24
Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest (2013) 1.21
Humans with atherosclerosis have impaired ABCA1 cholesterol efflux and enhanced high-density lipoprotein oxidation by myeloperoxidase. Circ Res (2014) 1.21
Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum (2012) 1.20
HDL as a biomarker, potential therapeutic target, and therapy. Diabetes (2009) 1.19
Dysfunctional HDL as a diagnostic and therapeutic target. Arterioscler Thromb Vasc Biol (2009) 1.17
The acute phase response inhibits reverse cholesterol transport. J Lipid Res (2010) 1.14
D-4F, an apoA-1 mimetic, decreases airway hyperresponsiveness, inflammation, and oxidative stress in a murine model of asthma. J Lipid Res (2010) 1.14
High interleukin-6 plasma levels are associated with low HDL-C levels in community-dwelling older adults: the InChianti study. Atherosclerosis (2006) 1.13
Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes (2011) 1.13
Genetic deletion of apolipoprotein A-I increases airway hyperresponsiveness, inflammation, and collagen deposition in the lung. J Lipid Res (2010) 1.12
Psoriasis alters HDL composition and cholesterol efflux capacity. J Lipid Res (2012) 1.11
High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscler Thromb Vasc Biol (2012) 1.11
Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol (2015) 1.11
New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids Health Dis (2011) 1.10
High density lipoproteins and endothelial functions: mechanistic insights and alterations in cardiovascular disease. J Lipid Res (2013) 1.09
Atherosclerosis and systemic lupus erythematosus: mechanistic basis of the association. Curr Opin Immunol (2007) 1.09
Apolipoprotein A-I mimetic peptide treatment inhibits inflammatory responses and improves survival in septic rats. Am J Physiol Heart Circ Physiol (2009) 1.07
A phospholipidomic analysis of all defined human plasma lipoproteins. Sci Rep (2011) 1.07
Evidence for association between paraoxonase-1 activity and diseases. Afr Health Sci (2013) 1.06
Serum levels of soluble receptor for advanced glycation end products and of S100 proteins are associated with inflammatory, autoantibody, and classical risk markers of joint and vascular damage in rheumatoid arthritis. Arthritis Res Ther (2009) 1.05
Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV. J Clin Invest (1997) 1.03
Identification of the prooxidant site of human ceruloplasmin: a model for oxidative damage by copper bound to protein surfaces. Proc Natl Acad Sci U S A (1997) 1.03
Friend Turns Foe: Transformation of Anti-Inflammatory HDL to Proinflammatory HDL during Acute-Phase Response. Cholesterol (2010) 1.02
Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care Res (Hoboken) (2010) 1.02
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol (2015) 1.00
HDL in humans with cardiovascular disease exhibits a proteomic signature. Clin Chim Acta (2010) 0.99
Obesity and altered glucose metabolism impact HDL composition in CETP transgenic mice: a role for ovarian hormones. J Lipid Res (2012) 0.99
Aging affects high-density lipoprotein composition and function. Biochim Biophys Acta (2013) 0.98
Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype. Atherosclerosis (2011) 0.97
Enhanced nitrosative stress during Trypanosoma cruzi infection causes nitrotyrosine modification of host proteins: implications in Chagas' disease. Am J Pathol (2008) 0.97
Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention. Expert Rev Clin Immunol (2011) 0.96
Molecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes. Vasc Health Risk Manag (2013) 0.94
Metabolic effects of obesity: A review. World J Diabetes (2010) 0.94
Antigen sensitization influences organophosphorus pesticide-induced airway hyperreactivity. Environ Health Perspect (2008) 0.94
Myeloperoxidase, inflammation, and dysfunctional high-density lipoprotein. J Clin Lipidol (2010) 0.94
Autoimmune-mediated reduction of high-density lipoprotein-cholesterol and paraoxonase 1 activity in systemic lupus erythematosus-prone gld mice. Arthritis Rheum (2011) 0.94
HDL dysfunction in diabetes: causes and possible treatments. Expert Rev Cardiovasc Ther (2012) 0.92
Anti-inflammatory mechanisms of apolipoprotein A-I mimetic peptide in acute respiratory distress syndrome secondary to sepsis. PLoS One (2013) 0.92
Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis. Adv Exp Med Biol (2015) 0.92
Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J Lipid Res (2015) 0.90
A novel anti-atherogenic role for COX-2--potential mechanism for the cardiovascular side effects of COX-2 inhibitors. Prostaglandins Other Lipid Mediat (2007) 0.89
Human experimental endotoxemia in modeling the pathophysiology, genomics, and therapeutics of innate immunity in complex cardiometabolic diseases. Arterioscler Thromb Vasc Biol (2014) 0.88
HDL-apoA-I exchange: rapid detection and association with atherosclerosis. PLoS One (2013) 0.86
Decreased paraoxonase activity in critically ill patients with sepsis. Clin Exp Med (2009) 0.86
The modification of serum lipids after acute coronary syndrome and importance in clinical practice. Curr Cardiol Rev (2011) 0.86
Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus. Clin Rheumatol (2008) 0.85
Gene and protein expression pilot profiling and biomarkers in an experimental mouse model of hypertensive glaucoma. Exp Biol Med (Maywood) (2009) 0.84
Dysfunctional high-density lipoprotein. Curr Opin Endocrinol Diabetes Obes (2009) 0.84
Anion exchange HPLC isolation of high-density lipoprotein (HDL) and on-line estimation of proinflammatory HDL. PLoS One (2014) 0.83
High density lipoproteins and atherosclerosis: emerging aspects. J Geriatr Cardiol (2012) 0.83
Thermal transitions in serum amyloid A in solution and on the lipid: implications for structure and stability of acute-phase HDL. J Lipid Res (2015) 0.83
HDL redox activity is increased in HIV-infected men in association with macrophage activation and non-calcified coronary atherosclerotic plaque. Antivir Ther (2014) 0.82
Combinations of Polymorphic Markers of Chemokine Genes, Their Receptors and Acute Phase Protein Genes As Potential Predictors of Coronary Heart Diseases. Acta Naturae (2016) 0.82
Cardiovascular disease and rheumatoid arthritis: an update. Curr Rheumatol Rep (2012) 0.81
Dyslipidemia and cardiovascular risk in human immunodeficiency virus infection. Endocrinol Metab Clin North Am (2014) 0.81
Cardiovascular risk in patients with rheumatoid arthritis. Semin Immunopathol (2017) 0.80
Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients. Br J Clin Pharmacol (2007) 0.80
Vasculoprotective Effects of Apolipoprotein Mimetic Peptides: An Evolving Paradigm In Hdl Therapy (Vascular Disease Prevention, In Press.). Vasc Dis Prev (2009) 0.80
A high throughput biochemical fluorometric method for measuring lipid peroxidation in HDL. PLoS One (2014) 0.80
Impaired HDL cholesterol efflux in metabolic syndrome is unrelated to glucose tolerance status: the CODAM study. Sci Rep (2016) 0.80
Mannose-Binding Lectin Levels and Carotid Intima-Media Thickness in Type 2 Diabetic Patients. J Diabetes Res (2015) 0.80
Anti-TNFα therapy transiently improves high density lipoprotein cholesterol levels and microvascular endothelial function in patients with rheumatoid arthritis: a pilot study. BMC Musculoskelet Disord (2012) 0.79
APOL1 G1 genotype modifies the association between HDLC and kidney function in African Americans. BMC Genomics (2015) 0.79
Residual Cardiovascular Risk in Chronic Kidney Disease: Role of High-density Lipoprotein. Arch Med Res (2015) 0.79
Association of pro-inflammatory high-density lipoprotein cholesterol with clinical and laboratory variables in sickle cell disease. Hematology (2014) 0.79
Pharmacological modulation by celecoxib of cachexia associated with experimental arthritis and atherosclerosis in rabbits. Br J Pharmacol (2010) 0.78
Serum amyloid A impairs the antiinflammatory properties of HDL. J Clin Invest (2015) 0.78
Persistence of an atherogenic lipid profile after treatment of acute infection with Brucella. J Lipid Res (2009) 0.78
Altered inflammation, paraoxonase-1 activity and HDL physicochemical properties in obese humans with and without Prader-Willi syndrome. Dis Model Mech (2012) 0.78
Lipoprotein carriers of microRNAs. Biochim Biophys Acta (2016) 0.78
Sphingosine 1-phosphate and its carrier apolipoprotein M in human sepsis and in Escherichia coli sepsis in baboons. J Cell Mol Med (2016) 0.78
The deleterious influence of tenofovir-based therapies on the progression of atherosclerosis in HIV-infected patients. Mediators Inflamm (2012) 0.78
Human plasma lipid modulation in schistosomiasis mansoni depends on apolipoprotein E polymorphism. PLoS One (2014) 0.78
Secretory Phospholipase A2 Is Associated with the Odds of Acute Coronary Syndromes through Elevation of Serum Amyloid-A Protein. Int J Angiol (2013) 0.78
Effects of urban fine particulate matter and ozone on HDL functionality. Part Fibre Toxicol (2016) 0.77
Paired measurements of paraoxonase 1 and serum amyloid A as useful disease markers. Biomed Res Int (2013) 0.77
Biochemical and functional characterization of charge-defined subfractions of high-density lipoprotein from normal adults. Anal Chem (2013) 0.76
Untrained young men have dysfunctional HDL compared with strength-trained men irrespective of body weight status. J Appl Physiol (1985) (2013) 0.76
The correlation between the cardio-ankle vascular index (CAVI) and serum amyloid A in asymptomatic Japanese subjects. Heart Vessels (2011) 0.76
Autoantibodies to apolipoprotein A-1 in cardiovascular diseases: current perspectives. Clin Dev Immunol (2012) 0.76
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem (1987) 281.19
The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest (1955) 31.08
The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med (1994) 8.10
Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol (1983) 7.47
Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest (1991) 6.50
Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A (1990) 4.34
Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes. Int J Cancer (1988) 3.66
NHLBI funding policies. Enhancing stability, predictability, and cost control. Circulation (1994) 3.11
Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett (1991) 3.10
Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest (1991) 3.07
Dietary induced atherogenesis in swine. Morphology of the intima in prelesion stages. Am J Pathol (1979) 3.04
Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos (1991) 2.51
High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta (1990) 2.42
Caeruloplasmin: physiological and pathological perspectives. Crit Rev Clin Lab Sci (1981) 2.32
LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis (1979) 2.21
The metabolic role of lecithin: cholesterol acyltransferase: perspectives form pathology. Adv Lipid Res (1973) 2.12
Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res (1989) 2.10
Amyloid protein SAA is an apoprotein of mouse plasma high density lipoprotein. Proc Natl Acad Sci U S A (1979) 1.91
Ceruloplasmin. A scavenger of superoxide anion radicals. J Biol Chem (1979) 1.84
Monocyte migration into the subendothelial space of a coculture of adult human aortic endothelial and smooth muscle cells. J Clin Invest (1988) 1.76
Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest (1995) 1.66
Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice. J Biol Chem (1993) 1.66
Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis (1991) 1.59
Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase. Eur J Biochem (1993) 1.57
Modification of the Recalde method for the isolation of human monocytes. J Lipid Res (1988) 1.55
Monocyte chemotactic factor produced by large vessel endothelial cells in vitro. Arteriosclerosis (1986) 1.54
Role of endothelial cells and their products in the modification of low-density lipoproteins. Biochim Biophys Acta (1986) 1.40
The inhibition of lipid autoxidation by human caeruloplasmin. Biochem J (1977) 1.32
Hydrolysis of phosphatidylcholine during LDL oxidation is mediated by platelet-activating factor acetylhydrolase. J Lipid Res (1989) 1.28
Purification of rabbit and human serum paraoxonase. Biochemistry (1991) 1.21
A fluorescence-based protein assay for use with a microplate reader. Anal Biochem (1993) 1.21
Platelet-activating factor acetylhydrolase from human plasma. Methods Enzymol (1990) 1.17
Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest (1994) 1.16
Distribution and localization of lecithin:cholesterol acyltransferase and cholesteryl ester transfer activity in A-I-containing lipoproteins. J Lipid Res (1986) 1.15
A spectrophotometric microtiter-based assay for the detection of hydroperoxy derivatives of linoleic acid. Anal Biochem (1992) 1.13
Inhibition of superoxide and ferritin-dependent lipid peroxidation by ceruloplasmin. J Biol Chem (1989) 1.07
Lipopolysaccharide-induced inhibition of scavenger receptor expression in human monocyte-macrophages is mediated through tumor necrosis factor-alpha. J Immunol (1992) 1.06
Protective effect of lipoproteins containing apoprotein A-I on Cu2+-catalyzed oxidation of human low density lipoprotein. FEBS Lett (1989) 1.06
Redox cycling of iron and lipid peroxidation. Lipids (1992) 1.04
Human serum amyloid A protein. Behaviour in aqueous and urea-containing solutions and antibody production. Biochem J (1989) 1.03
The platelet-activating factor acetylhydrolase from human erythrocytes. Purification and properties. J Biol Chem (1993) 1.01
Is paraoxonase related to atherosclerosis. Chem Biol Interact (1993) 0.96
Interaction of very low density lipoproteins (VLDL) with rabbit C-reactive protein. J Immunol (1982) 0.94
Molecular and cellular biology of serum amyloid A. Mol Biol Med (1990) 0.92
Acidic pH enables caeruloplasmin to catalyse the modification of low-density lipoprotein. FEBS Lett (1994) 0.90
Radioiodination of low density lipoprotein initiates lipid peroxidation: protection by use of antioxidants. J Lipid Res (1993) 0.89
Low density lipoprotein oxidation by stimulated neutrophils and ferritin. Atherosclerosis (1992) 0.88
Detection of multiple forms of human ceruloplasmin. A novel Mr 200,000 form. J Biol Chem (1990) 0.88
Isolation of nonlabile human ceruloplasmin by chromatographic removal of a plasma metalloproteinase. Arch Biochem Biophys (1994) 0.86
Major acute-phase reactant synthesis during chronic inflammation in amyloid-susceptible and -resistant mouse strains. Inflammation (1991) 0.86
Zinc, copper and ceruloplasmin in arteriosclerosis. Biomedicine (1976) 0.85
Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature (1990) 5.17
Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A (1980) 4.66
Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A (1990) 4.34
Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem (1997) 3.91
Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature (1998) 3.84
Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation (1995) 3.82
Platelet-activating factor and related lipid mediators. Annu Rev Biochem (2000) 3.44
Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest (1990) 3.40
Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest (1998) 3.34
Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest (1995) 3.23
Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low-density lipoproteins. Nature (1990) 3.11
Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest (1991) 3.07
Endothelial cell interactions with granulocytes: tethering and signaling molecules. Immunol Today (1992) 3.06
Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: a juxtacrine system for adhesion and activation of neutrophils. J Cell Biol (1991) 3.05
Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest (2001) 3.01
Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature (1995) 2.79
Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta (1981) 2.77
Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. J Cell Biol (2001) 2.75
The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet (1983) 2.66
Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem (1993) 2.61
Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils. J Cell Biol (1991) 2.59
Thrombin stimulates the adherence of neutrophils to human endothelial cells in vitro. J Clin Invest (1985) 2.58
The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol (1996) 2.56
Genetic locus in mice that blocks development of atherosclerosis despite extreme hyperlipidemia. Circ Res (2001) 2.55
Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest (1996) 2.51
Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities. Drug Metab Dispos (1991) 2.51
The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics (1996) 2.48
Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J Exp Med (1992) 2.47
Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. Nat Genet (1993) 2.44
A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res (2001) 2.38
Treponema pallidum invades intercellular junctions of endothelial cell monolayers. Proc Natl Acad Sci U S A (1988) 2.37
Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein. J Exp Med (1982) 2.33
Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proc Natl Acad Sci U S A (1984) 2.28
Structure of the gene for human butyrylcholinesterase. Evidence for a single copy. Biochemistry (1990) 2.26
Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J Biol Chem (1986) 2.25
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3. J Lipid Res (2000) 2.22
Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest (1996) 2.21
Protein kinase C regulates the nuclear localization of diacylglycerol kinase-zeta. Nature (1998) 2.20
Leukotrienes C4 and D4 stimulate human endothelial cells to synthesize platelet-activating factor and bind neutrophils. Proc Natl Acad Sci U S A (1986) 2.18
Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. J Clin Invest (1985) 2.16
Platelet-activating factor. J Biol Chem (1990) 2.13
Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet (1993) 2.12
Neutrophil adherence to human endothelium in vitro occurs by CDw18 (Mo1, MAC-1/LFA-1/GP 150,95) glycoprotein-dependent and -independent mechanisms. J Clin Invest (1988) 2.12
Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res (2001) 2.11
Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol (1979) 2.08
Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem (2001) 2.08
Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br Heart J (1982) 2.07
Monocyte tethering by P-selectin regulates monocyte chemotactic protein-1 and tumor necrosis factor-alpha secretion. Signal integration and NF-kappa B translocation. J Clin Invest (1995) 2.06
Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res (2000) 2.05
Post-transcriptional control of cyclooxygenase-2 gene expression. The role of the 3'-untranslated region. J Biol Chem (2000) 2.05
Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc Natl Acad Sci U S A (1982) 2.04
Phylogenetic aspects of C-reactive protein and related proteins. Ann N Y Acad Sci (1982) 2.03
Lhermitte-Duclos disease and Cowden disease: a single phakomatosis. Ann Neurol (1991) 2.01
Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci U S A (1998) 1.97
The metabolism of native and malondialdehyde-altered low density lipoproteins by human monocyte-macrophages. J Lipid Res (1981) 1.97
Human plasma platelet-activating factor acetylhydrolase. Association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem (1987) 1.93
Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci U S A (1996) 1.88
Inflammatory roles of P-selectin. J Clin Invest (1993) 1.87
Vitamin C blocks inflammatory platelet-activating factor mimetics created by cigarette smoking. J Clin Invest (1997) 1.87
Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor gamma ligands and agonists. J Biol Chem (2001) 1.86